MDR Revision Is More Restrictive, Misses Opportunities – NEMA, AdvaMed
This article was originally published in The Gray Sheet
Executive Summary
FDA should withdraw its medical device reporting direct final rule and "proceed with the usual procedures for notice and comment on the companion proposed rule," NEMA asserts in a May 12 FDL-1letter to the agency